Q-omics provides the consensus-scored GUCY2GP profile across patient tissues and cancer cell-line models. GUCY2GP expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GUCY2GP is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, GUCY2GP RNA expression shows 7,668 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, and ESCA as cancer lineages where GUCY2GP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCY2GP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCY2GP survival associations across molecular data types. GUCY2GP RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCY2GP RNA expression–survival associations across cancer types. High GUCY2GP expression shows unfavorable associations in KIRC and ESCA, but favorable associations in STAD, LAML, UVM and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GUCY2GP RNA expression.
This table summarizes GUCY2GP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GUCY2GP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCY2GP shows lower tumor expression in KIRC, KICH, KIRP and BRCA and higher tumor expression in LUAD and LIHC. The KIRC box plot shows higher GUCY2GP RNA expression in normal versus tumor tissue (log2 FC = −0.026, t-test p < 0.001).
This table shows molecular features associated with GUCY2GP in patient tissues and cancer cell lines. In patient samples, GUCY2GP shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
